QNRX · Quoin Pharmaceuticals Ltd. American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow QNRX by emailGet an email when QNRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QNRX, unsubscribe in one click. Privacy
📣 What QNRX Says Is Next
second half of 2026 · “Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.”
Company press release, Sep 22, 2026 · SEC filing
in 2028 · “Quoin is targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028.”
Company press release, Sep 22, 2026 · SEC filing
second half of 2026 · “We expect to initiate our Phase 2/3 study in the second half of 2026, and we believe Fast Track status will allow us to work closely with the agency as we advance the first company-sponsored clinical study in this disease.” Peeling Skin Syndrome Development Program The planned Phase 2/3 study is expected to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe.”
Company press release, Sep 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full QNRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QNRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.